The novel coronavirus (COVID-19) has spread rapidly and become a severe global threat, with a reported acute respiratory distress syndrome (ARDS) incidence up to 40% [1]. According to a large survey, more than 14% patients were transferred to the intensive care unit care (ICU), and among those who received invasive mechanical ventilation, the mortality was as high as 88.1% [2].
Here we presented the data from a single ICU of Tianyou hospital in Wuhan, and according our experience, the overall mortality decreased in patients receiving Chinese herb therapy. From January 11, 2020, to March 17, 2020, a total of 37 patients confirmed with COVID-19 infection were admitted to ICU (Table 1), of whom seven patients were transferred to other hospitals and were excluded from this analysis. The general treatment regimens included glucocorticoids, antibiotics, hydroxychloroquine, and arbidol; however, the overall mortality rate remains as high as 78.1%. Chinese herb was applied in these patients since Feb 17. Thus, a total of nine patients received Chinese herbal therapy during the whole disease course (admitted to ICU after Feb 17), five patients received Chinese herbal therapy for a period of the whole disease course, and the rest fourteen patients had not received Chinese herbal therapy. Despite with limited sample size, the mortality rate decreased significantly after applying Chinese herbal to these patients (4/9 vs. 5/5 vs. 14/16, p = 0.033), especially in patients who received Chinese herbal therapy during the whole disease course. Further, these patients were also divided into two groups according to whether they had used Chinese herbal; a decreased trend of mortality was also observed (9/14 vs. 14/16, p = 0.134).
Table 1
Comparisons between survivors and non-survivors with coronavirus infection
Variables | All patients (n = 30) | Survivors (n = 7) | Non-survivors (n = 23) | p |
|---|---|---|---|---|
Gender (male, %) | 19 (63.3) | 7 (100) | 12 (52.1) | 0.029 |
Age (years, %) | 67.4 ± 9.2 | 65.7 ± 9.7 | 67.9 ± 9.2 | 0.582 |
PaO2/FiO2 | 107.7 ± 54.5 | 122.5 ± 52.3 | 102.2 ± 55.6 | 0.410 |
ICU length of stay | 10.5 (5–14) | 12 (10–12) | 10 (4–15) | 0.402 |
Intubation rate (%) | 18 (60.0) | 3 (42.8) | 15 (65.2) | 0.290 |
Comorbidities | ||||
Hypertension (%) | 10 (33.3) | 3 (42.8) | 7 (30.4) | 0.657 |
Diabetes (%) | 7 (23.3) | 1 (14.2) | 6 (26.0) | 1.000 |
Use of Chinese herbal | 0.033 | |||
The whole course (%) | 9 (30) | 5 (71.4) | 4 (17.3) | |
Part of the course (%) | 5 (16.7) | 0 (0) | 5 (21.7) | |
Not used (%) | 16 (53.3) | 2 (28.5) | 14 (60.8) | |
Anzeige
We understand our finding is unstable due to the limited sample size and potential cofounders. However, in China, Chinese herbal therapy has been fully applied to patients with COVID-19 infection in the middle stage of this epidemic and the effect is positive. The following content is the main Chinese herbal formulas for these nine patients:
-
Formula 1: Xinren, Shigao, Gualuo, Dahuang, Mahuang, Tinglizi, Taoren, Caoguo, Binglang, Cangshu, Jinyinhua, Lianqiao, Hongjingtian.
-
Formula 2: Fuzhi, Shengjiang, Huangqi, Renshen, Xinren, Shigao, Gualuo, Dahuang, Mahuang, Tinglizi, Taoren, Caoguo, Binglang, Cangshu, Gancao.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
None.
Anzeige
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
